Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
mercredi, octobre 07
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Milestone Scientific Inc
MLSS
AMEX
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$0.3700
0.0029
0.79%
Dern. MÀJ: Oct 6, 7:30 PM
$0.3900
0.0229
6.24%
Get Report
Aperçu
Actualités
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Actionnariat
Comparer
Options
Rapport sur les stocks
Privacy Manager
Milestone Scientific Financials
Milestone Scientific (MLSS) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Conference Call: Milestone Scientific Affirms FY2026 Sales Guidance of $9.800M-$10.200M vs $9.910M Est
Milestone Scientific (AMEX:MLSS) affirms FY2026 sales outlook from $9.800 million-$10.200 million to $9.800 million-$10.200 million vs $9.910 million estimate.
Benzinga Newsdesk
PRO
Conference Call: Milestone Scientific Sees Q3 Sales $2.300M-$2.500M vs $2.510M Est
Milestone Scientific (AMEX:MLSS) sees Q3 sales of $2.300 million-$2.500 million vs $2.510 million analyst estimate.
Benzinga Newsdesk
PRO
Milestone Scientific Q2 EPS $(0.01), Inline, Sales $2.841M Beat $2.700M Estimate
Milestone Scientific (AMEX:MLSS) reported quarterly losses of $(0.01) per share which met the analyst consensus estimate. This is a 50 percent increase over losses of $(0.02) per share from the same period last year.
Benzinga Newsdesk
PRO
Milestone Scientific Expects Q2 Revenue Of ~$2.8M, Up 21% YoY; H1 Revenue Of ~$5M, Up 9% YoY
Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced preliminary, unaudited revenue for the second quarter
Benzinga Newsdesk
PRO
Reported earlier, Milestone Scientific Affirms FY2026 Sales Guidance of $9.800M-$10.200M vs $9.910M Est
Milestone Scientific (AMEX:MLSS) affirms FY2026 sales outlook from $9.800 million-$10.200 million to $9.800 million-$10.200 million vs $9.910 million estimate.
Benzinga Newsdesk
PRO
Milestone Scientific Q1 EPS $(0.01), Inline, Sales $2.162M Miss $2.252M Estimate
Milestone Scientific (AMEX:MLSS) reported quarterly losses of $(0.01) per share which met the analyst consensus estimate. This is a 50 percent increase over losses of $(0.02) per share from the same period last year.
Benzinga Newsdesk
